 |
Exendin 9-39 (Competitive antagonist of glucagon-like peptide-1) |
|---|---|
| Trade Name | |
| Orphan Indication | Hyperinsulinemic hypoglycemia |
| USA Market Approval | USA |
| USA Designation Date | 2016-12-08 00:00:00 |
| Sponsor | Eiger BioPharmaceuticals, Inc.;350 Cambridge Avenue, Suite 350;Palo Alto, California, 94306 |
